StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)

Close on Nov 17, 2026Market cap $5.63BP/E –Yield –

Caris Life Sciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Caris Life Sciences's price to sales ratio was 7.0× on Nov 11, 2026, against 11.1× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.0×−4.7
2025Dec 31, 202511.7×–

More Caris Life Sciences figures

See a number that looks wrong?